ARCA biopharma, Inc. (NASDAQ:ABIO) Issues Quarterly Earnings Results
ARCA biopharma, Inc. (NASDAQ:ABIO) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, Bloomberg Earnings reports.
ARCA biopharma (NASDAQ ABIO) traded down 7.32% during trading on Friday, reaching $1.90. 194,197 shares of the company’s stock traded hands. The firm’s 50 day moving average is $2.38 and its 200 day moving average is $2.46. ARCA biopharma has a 12 month low of $1.65 and a 12 month high of $3.20. The company’s market cap is $17.56 million.
TRADEMARK VIOLATION NOTICE: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/08/05/arca-biopharma-inc-nasdaqabio-issues-quarterly-earnings-results.html.
About ARCA biopharma
ARCA biopharma, Inc (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF).
Receive News & Ratings for ARCA biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARCA biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.